Processa Seeks Reverse Split Approval to Meet Nasdaq $4.00 Listing Requirement
PCSA sits 41% above its 52-week low of $1.041 on elevated volume (11× avg).
Summary
Processa Pharmaceuticals filed a preliminary proxy seeking shareholder approval for a reverse stock split between 1-for-3 and 1-for-9 to meet Nasdaq's $4.00 minimum price requirement, a necessary step before converting 306.6 million Series A Preferred shares and completing its Vidya Therapeutics rebranding.
Key Events · Corporate Governance and Compliance · PCSA
-
Reverse Split Proposal Filed
Board seeks approval for a reverse stock split at a ratio between 1-for-3 and 1-for-9, with the final ratio to be determined by the Board within one year of the special meeting.
-
Nasdaq $4.00 Minimum Price Requirement
The reverse split is needed to lift the stock price above Nasdaq's $4.00 initial listing threshold, required because the Series A Preferred conversion will trigger a Change of Control under Nasdaq Rule 5110(a).
-
306.6M Share Conversion Blocked
306,574,202 Series A Preferred shares (convertible into 306.6 million common shares) cannot convert until shareholders approve the conversion at a separate future meeting, which cannot occur until Nasdaq initial listing is conditionally approved.
-
Rebrand to Vidya Therapeutics
Upon Nasdaq approval, the company expects to change its name to Vidya Therapeutics, Inc. and trade under ticker VDYA.
Analysis · PCSA · Life Sciences
Processa is asking shareholders to approve a reverse stock split of between 1-for-3 and 1-for-9 to lift its share price above Nasdaq's $4.00 minimum initial listing threshold. The split is a prerequisite for converting 306.6 million Series A Preferred shares into common stock — a conversion that would trigger a Change of Control under Nasdaq rules and require the company to complete a full initial listing application. Without the split, the company cannot complete the Vidya merger integration or unlock the $200 million PIPE capital structure. The filing also confirms the company plans to rename to Vidya Therapeutics and trade under ticker VDYA.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 28.2% of the 1631 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSA was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.04 to $11.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.